Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat
- PMID: 288932
- DOI: 10.1093/jnci/63.3.727
Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat
Abstract
beta-Cytosine arabinoside (Ara-C) in free and liposome encapsulated form was administered to Wistar rats by intratracheal institution. Free [3H]Ara-C administered in this manner rapidly left the lung and entered the systemic circulation. Liposome-encapsulated [3H]Ara-C persisted in the lung for a long period, with little redistribution to other tissues. Liposomes administered via the trachea became widely distributed throughout the lung air spaces, as evidenced by the histochemical localization of liposomes containing horse-radish peroxidase. Free Ara-C (5 mg/kg) administered into the trachea effectively suppressed macromolecular incorporation of [14C]thymidine ([14C]dThd) in the bone marrow and gut as well as in the lung. Liposome-encapsulated Ara-C (5 mg/kg) effectively suppressed macromolecular incorporation of [14C]dThd in the lung but had little effect on this process in the gut and bone marrow. Our results suggest that liposome-encapsulated Ara-C may be able to produce a local pharmacologic effect within the lung without producing adverse side effects in other tissues. This observation may be relevant to the chemotherapy of pulmonary metastases.
Similar articles
-
Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.J Pharmacol Exp Ther. 1980 Aug;214(2):381-7. J Pharmacol Exp Ther. 1980. PMID: 7391983
-
Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.Drug Metab Dispos. 1982 Jan-Feb;10(1):40-6. Drug Metab Dispos. 1982. PMID: 6124381
-
Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.Int J Cancer. 1986 Jan 15;37(1):149-54. doi: 10.1002/ijc.2910370123. Int J Cancer. 1986. PMID: 3941019
-
[Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].Gan To Kagaku Ryoho. 1982 Aug;9(8):1339-51. Gan To Kagaku Ryoho. 1982. PMID: 6191711 Review. Japanese.
-
Immunoglobulins as targeting agents for liposome encapsulated drugs.Pharm Weekbl Sci. 1983 Dec 16;5(6):269-80. doi: 10.1007/BF02074854. Pharm Weekbl Sci. 1983. PMID: 6364035 Review.
Cited by
-
Nebulization of liposomes. I. Effects of lipid composition.Pharm Res. 1990 Nov;7(11):1127-33. doi: 10.1023/a:1015924124180. Pharm Res. 1990. PMID: 2293210
-
The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.Pharm Res. 2011 Sep;28(9):2233-45. doi: 10.1007/s11095-011-0454-1. Epub 2011 Jun 7. Pharm Res. 2011. PMID: 21647791
-
Liposomes for controlled delivery of drugs to the lung.Thorax. 1992 Apr;47(4):257-9. doi: 10.1136/thx.47.4.257. Thorax. 1992. PMID: 1585287 Free PMC article. No abstract available.
-
Use of monoclonal antibodies and liposomes to improve drug delivery. Present status and future implications.Drugs. 1982 Oct;24(4):261-6. doi: 10.2165/00003495-198224040-00001. Drugs. 1982. PMID: 7140578 No abstract available.
-
A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation.AAPS PharmSciTech. 2010 Sep;11(3):1411-21. doi: 10.1208/s12249-010-9500-2. Epub 2010 Sep 15. AAPS PharmSciTech. 2010. PMID: 20839079 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources